ACLX Stock Price, Arcellx, Inc. Quote, Chart

Market Summary

USD53.11+2.49

Delayedas of 15 May 2024, 11:53 am

4.92%

ACLX Alerts

2 major insider sales recently.

Big jump in Earnings (Y/Y)
Losses in recent quarter

ACLX Stock Price

View Fullscreen

ACLX RSI Chart

ACLX Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-53.58

Price/Sales (Trailing)

20.57

EV/EBITDA

-53.4

Price/Free Cashflow

-81.44

ACLX Price/Sales (Trailing)

ACLX Profitability

EBT Margin

-38.14%

Return on Equity

-10.18%

Return on Assets

-6.48%

Free Cashflow Yield

-1.23%

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

131.7M

Rev. Growth (Qtr)

-37.83%

ACLX Earnings

Earnings (TTM)

-50.5M

Earnings Growth (Yr)

73.68%

Earnings Growth (Qtr)

-136.27%

Breaking Down ACLX Revenue

52 Week Range

30.7454.30

(Low)(High)

Last 7 days

-3.4%

Last 30 days

-12.8%

Last 90 days

-21.4%

Trailing 12 Months

16.6%

How does ACLX drawdown profile look like?

ACLX Financial Health

Current Ratio

5.46

ACLX Investor Care

Shares Dilution (1Y)

11.48%

Diluted EPS (TTM)

-1.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	131.7M	0	0	0
2023	0	0	0	110.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcellx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	heery christopher	sold	-932,557	51.3296	-18,168	chief medical officer
May 01, 2024	heery christopher	acquired	114,095	6.28	18,168	chief medical officer
Apr 16, 2024	ware olivia c	acquired	71,549	7.61	9,402	-
Apr 16, 2024	ware olivia c	sold	-522,260	55.5477	-9,402	-
Apr 01, 2024	elghandour rami	sold	-1,548,890	67.092	-23,086	see remarks
Mar 26, 2024	heery christopher	sold	-376,648	69.1097	-5,450	chief medical officer
Mar 26, 2024	heery christopher	acquired	34,226	6.28	5,450	chief medical officer
Mar 22, 2024	heery christopher	sold	-2,903,070	70.1817	-41,365	chief medical officer
Mar 22, 2024	heery christopher	acquired	125,600	6.28	20,000	chief medical officer
Mar 21, 2024	carroll jill	sold	-35,575,800	70.55	-504,263	-

Which funds bought or sold ACLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Advantage Alpha Capital Partners LP	reduced	-31.75	-182,066	1,076,290	0.20%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-3,391,000	-	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	new	-	49,740	49,740	-%
May 13, 2024	Jump Financial, LLC	reduced	-38.68	-195,145	647,511	0.02%
May 13, 2024	E Fund Management Co., Ltd.	reduced	-0.43	82,660	416,326	0.03%
May 13, 2024	FMR LLC	added	23.19	132,143,000	375,187,000	0.03%
May 13, 2024	SUMMIT SECURITIES GROUP LLC	new	-	3,000	3,000	-%
May 13, 2024	SEVEN EIGHT CAPITAL, LP	new	-	1,206,760	1,206,760	0.13%
May 13, 2024	FIRST TRUST ADVISORS LP	added	57.92	1,385,740	2,801,260	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	6.76	14,728,800	58,322,900	-%

Are Funds Buying or Selling ACLX?

Are funds buying ACLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACLX

No. of Funds

Unveiling Arcellx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	fmr llc	-	0	SC 13G/A
Mar 25, 2024	sr one capital management, llc	4.44%	2,346,630	SC 13D/A
Feb 14, 2024	paradigm biocapital advisors lp	7.0%	3,658,624	SC 13G/A
Feb 14, 2024	perceptive advisors llc	8.8%	4,544,809	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	5.0%	2,435,974	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 29, 2024	blackrock inc.	6.2%	3,018,538	SC 13G
Dec 28, 2023	gilead sciences, inc.	12.9%	6,720,803	SC 13G/A
Dec 18, 2023	sr one capital management, llc	6.46%	3,146,630	SC 13D/A
Jul 21, 2023	paradigm biocapital advisors lp	5.05%	2,422,700	SC 13G

Recent SEC filings of Arcellx, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Arcellx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Arcellx, Inc. News

Latest updates

Arcellx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	-37.8%	39,256,000	63,148,000	14,957,000	14,302,000	17,912,000
Operating Expenses	14.4%	55,066,000	48,149,000	59,819,000	43,862,000	48,369,000
S&GA Expenses	-100.0%	-	19,365,500	16,012,000	15,535,000	15,437,000
R&D Expenses	12.3%	32,318,000	28,783,500	43,807,000	28,327,000	32,932,000
EBITDA Margin	41.1%	-0.36	-0.62	-	-	-
Income Taxes	-100.0%	-	636,500	-6,000	-282,000	300,000
Earnings Before Taxes	-135.2%	-7,198,000	20,466,000	-39,342,000	-24,136,000	-27,015,000
EBT Margin	39.9%	-0.38	-0.63	-	-	-
Net Income	-136.3%	-7,198,000	19,844,000	-39,336,000	-23,854,000	-27,344,000
Net Income Margin	40.1%	-0.38	-0.64	-	-	-
Free Cashflow	-172.4%	-38,339,000	52,955,000	-18,029,000	-29,843,000	181,062,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-5.5%	780	825	614	624	623	314	337	375	247	129	58.00
Current Assets	-17.8%	589	716	491	558	571	267	290	325	224	113	49.00
Cash Equivalents	-60.2%	157	395	126	304	275	64.00	57.00	165	127	31.00	47.00
Net PPE	5.2%	45.00	43.00	38.00	22.00	14.00	11.00	10.00	10.00	10.00	10.00	5.00
Liabilities	-16.7%	283	340	348	330	319	109	101	51.00	19.00	17.00	7.00
Current Liabilities	-8.7%	108	118	173	156	166	57.00	45.00	24.00	14.00	15.00	5.00
Shareholder's Equity	2.3%	497	485	266	294	304	205	236	324	228	-	-
Retained Earnings	-1.8%	-396	-389	-409	-370	-346	-318	-279	-186	-156	-130	-65.14
Additional Paid-In Capital	2.2%	894	874	675	664	650	524	516	511	384	9.00	1.00
Shares Outstanding	1.9%	53.00	52.00	49.00	48.00	48.00	44.00	34.00	29.00	21.00	-	0.00
Float	-	-	-	-	1,300	-	-	-	453	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-154.8%	-31.91	58.00	-10.10	-22.61	182	-27.52	-16.65	-22.55	-32.59	-21.55	-12.22	-10.96	-9.51	-
Share Based Compensation	39.8%	15.00	11.00	11.00	10.00	10.00	6.00	5.00	6.00	4.00	3.00	2.00	1.00	1.00	-
Cashflow From Investing	-1084.0%	-206	21.00	-160	51.00	-66.77	34.00	-81.42	-59.23	-10.64	-17.66	-61.07	-0.18	-1.07	-
Cashflow From Financing	-101.6%	-2.98	189	-4.99	0.00	95.00	1.00	-9.71	121	140	0.00	-0.47	37.00	82.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACLX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue from related party	$ 39,256	$ 17,912
Operating expenses:
Research and development	32,318	32,932
General and administrative	22,748	15,437
Total operating expenses	55,066	48,369
Loss from operations	(15,810)	(30,457)
Other income (expense):
Interest income, net	9,200	4,468
Interest expense	(588)	(1,026)
Total other income, net	8,612	3,442
Loss before income taxes	(7,198)	(27,015)
Income tax expense	0	329
Net loss	(7,198)	(27,344)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	(1,059)	307
Comprehensive loss	$ (8,257)	$ (27,037)
Net loss per share attributable to common stockholders - basic	$ (0.14)	$ (0.58)
Net loss per share attributable to common stockholders - diluted	$ (0.14)	$ (0.58)
Weighted-average common shares outstanding - basic	52,757,973	46,769,380
Weighted-average common shares outstanding - diluted	52,757,973	46,769,380

ACLX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets, Current [Abstract]
Cash and cash equivalents	$ 154,574	$ 394,583
Marketable securities	419,345	307,434
Restricted cash, current	208	1,903
Prepaid expenses and other current assets	14,606	12,443
Total current assets	588,733	716,363
Restricted cash, non-current	2,418	2,418
Marketable securities non current	117,102	27,168
Property and equipment, net	44,930	42,728
Operating lease right-of-use assets	24,196	27,099
Prepaid research and development expenses and other long-term assets	2,316	9,356
Total assets	779,695	825,132
Current liabilities:
Accounts payable	3,099	2,619
Accrued liabilities	33,933	18,302
Operating lease liabilities, current portion	7,146	7,501
Finance lease liabilities, current portion	32,531	39,283
Contract liability to related party	31,192	50,533
Total current liabilities	107,901	118,238
Operating lease liabilities, net of current portion	47,685	50,841
Contract liability, net of current portion to related party	112,068	170,673
Other non-current liabilities	15,468
Total liabilities	283,122	339,752
Commitments and contingencies (Note 7)
Stockholders' equity
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 53,287,990 shares issued and outstanding as of March 31, 2024; 1,000,000,000 shares authorized and 52,280,077 shares issued and outstanding as of December 31, 2023	53	52
Additional paid-in capital	893,710	874,261
Accumulated other comprehensive income (loss)	(512)	547
Accumulated Deficit	(396,678)	(389,480)
Total stockholders' equity	496,573	485,380
Total liabilities and stockholders' equity	$ 779,695	$ 825,132

About Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

CEO	Mr. Rami Elghandour
WEBSITE	https://arcellx.com
INDUSTRY	Biotechnology
EMPLOYEES	98

Arcellx, Inc. Frequently Asked Questions

What is the ticker symbol for Arcellx, Inc.? What does ACLX stand for in stocks?

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcellx, Inc. (ACLX)?

As of Tue May 14 2024, market cap of Arcellx, Inc. is 2.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers. The fair value of Arcellx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcellx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcellx, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

What is Arcellx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, ACLX's PE ratio (Price to Earnings) is -53.58 and Price to Sales (PS) ratio is 20.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.